Craig Hallum Lowers CVRx (NASDAQ:CVRX) Price Target to $15.00

CVRx (NASDAQ:CVRX) had its price objective decreased by stock analysts at Craig Hallum from $23.00 to $15.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Craig Hallum’s price objective suggests a potential upside of 54.32% from the stock’s previous close.

Several other analysts have also recently weighed in on CVRX. William Blair cut shares of CVRx from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. lowered shares of CVRx from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $36.00 to $13.00 in a research report on Wednesday, May 1st. Piper Sandler lowered their target price on shares of CVRx from $33.00 to $15.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 1st. Canaccord Genuity Group lowered their target price on shares of CVRx from $32.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 1st. Finally, Lake Street Capital lowered their target price on shares of CVRx from $18.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $13.80.

CVRx Stock Up 14.2 %

NASDAQ:CVRX opened at $9.72 on Thursday. The company has a market cap of $209.91 million, a PE ratio of -3.94 and a beta of 1.27. CVRx has a twelve month low of $6.40 and a twelve month high of $33.13. The company has a current ratio of 12.18, a quick ratio of 10.87 and a debt-to-equity ratio of 0.44. The company’s 50 day moving average is $9.28 and its two-hundred day moving average is $17.53.

CVRx (NASDAQ:CVRX) last posted its earnings results on Tuesday, April 30th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.51). The firm had revenue of $10.77 million during the quarter, compared to analyst estimates of $11.60 million. CVRx had a negative net margin of 123.58% and a negative return on equity of 66.05%. Analysts anticipate that CVRx will post -2.39 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CVRX. Federated Hermes Inc. acquired a new stake in CVRx in the 4th quarter valued at $102,000. Valeo Financial Advisors LLC acquired a new stake in CVRx in the 1st quarter valued at $346,000. FourWorld Capital Management LLC acquired a new stake in CVRx in the 1st quarter valued at $374,000. Trexquant Investment LP acquired a new stake in CVRx in the 4th quarter valued at $426,000. Finally, Jump Financial LLC acquired a new stake in CVRx in the 4th quarter valued at $499,000. 75.27% of the stock is owned by institutional investors.

CVRx Company Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.